|Bid||27.69 x 800|
|Ask||38.50 x 800|
|Day's Range||36.88 - 37.62|
|52 Week Range||19.85 - 57.20|
|Beta (5Y Monthly)||2.43|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 07, 2022 - Nov 11, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||65.67|
Celldex (CLDX) delivered earnings and revenue surprises of -34.88% and 53.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- Positive interim data from barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria presented at EAACI 2022 - - First patients dosed in Phase 2 chronic urticaria studies - HAMPTON, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update. “In late June, Celldex reported positive interim data from our ongoing Phase 1b study of barzolvolimab in chronic spontane
HAMPTON, N.J., July 21, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CIndU) - cold urticaria (ColdU) and symptomatic dermographism (SD). Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity.